Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 2, 2001, Pages 103-110

  Spear, Gregory T ^a   Olinger, Gene G ^a   Saifuddin, Mohammed ^a   Gebel, Howard M ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Alloantibody; Alloantigen; Alloimmunization; Complement; HLA; MHC

Indexed keywords

ALLOANTIBODY; ALLOANTIGEN; CELL PROTEIN; COMPLEMENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ABSORPTION; ALLOIMMUNIZATION; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

EID: 0035251416     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200102010-00001     Document Type: Article

References (39)

1. Nonrandom association of cellular antigens with HTLV-III virions
2. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV
3. Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type I
4. Inhibition of human immunodeficiency virus infection in monocytes by monoclonal antibodies against leukocyte adhesion molecules
5. Host cell membrane proteins on human immunodeficiency virus type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscopic study
6. Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis
7. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines
8. Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1
9. Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1
10. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis
11. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-I
12. Role of complement in HIV infection
13. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts
14. Efficient incorporation of HLA class II onto human immunodeficiency virus type 1 requires envelope glycoprotein packaging
15. Anti-cell antibody in macaques
16. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus
17. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response
18. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus
19. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H
20. Anti-major histocompatibility complex antibody responses in macaques via intradermal DNA immunizations
21. Alloimmunization as an AIDS vaccine?
22. Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS
23. Strategies for AIDS vaccines
24. Alloimmunization to prevent AIDS?
25. Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients
26. A vaccine for HIV type 1: The antibody perspective
27. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
28. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
29. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
30. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis
31. Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes
32. Sensitization and sensitivity: Defining the unsensitized patient
33. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus
34. Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test
35. Comparison of MHC antigen expression on PHA- and MLC-induced T cell lines with that on T and B lymphoblastoid cell lines by cell cycle dependency
36. Cell culture density modulates the incorporation of HLA antigens by enveloped viruses
37. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism
38. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection
39. Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection